Clinical Trial Detail

NCT ID NCT02780011
Title Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors The Methodist Hospital System
Indications

skin angiosarcoma

embryonal testis carcinoma

lymphoma

Advanced Solid Tumor

nasopharynx carcinoma

Therapies

Alisertib + Brentuximab vedotin

Age Groups: adult

No variant requirements are available.